12,187 Shares in Verve Therapeutics, Inc. (NASDAQ:VERV) Purchased by SVB Wealth LLC

SVB Wealth LLC purchased a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,187 shares of the company’s stock, valued at approximately $170,000.

Other hedge funds have also recently modified their holdings of the company. International Assets Investment Management LLC acquired a new position in shares of Verve Therapeutics during the 4th quarter worth about $97,000. China Universal Asset Management Co. Ltd. raised its position in shares of Verve Therapeutics by 437.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,815 shares of the company’s stock worth $123,000 after purchasing an additional 7,174 shares during the last quarter. Merit Financial Group LLC acquired a new stake in Verve Therapeutics in the 3rd quarter valued at about $151,000. Teacher Retirement System of Texas raised its holdings in Verve Therapeutics by 10.8% in the 3rd quarter. Teacher Retirement System of Texas now owns 12,058 shares of the company’s stock valued at $160,000 after acquiring an additional 1,174 shares during the last quarter. Finally, Arizona State Retirement System raised its holdings in Verve Therapeutics by 9.3% in the 3rd quarter. Arizona State Retirement System now owns 12,343 shares of the company’s stock valued at $164,000 after acquiring an additional 1,054 shares during the last quarter. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Price Performance

Shares of VERV stock opened at $6.88 on Wednesday. Verve Therapeutics, Inc. has a 52 week low of $6.42 and a 52 week high of $21.42. The firm has a 50 day moving average of $12.04 and a two-hundred day moving average of $12.29.

Verve Therapeutics (NASDAQ:VERV) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.14. Verve Therapeutics had a negative net margin of 1,701.70% and a negative return on equity of 39.33%. The company had revenue of $5.14 million during the quarter, compared to analysts’ expectations of $3.95 million. As a group, analysts anticipate that Verve Therapeutics, Inc. will post -2.92 EPS for the current year.

Analysts Set New Price Targets

VERV has been the subject of a number of recent research reports. Stifel Nicolaus cut their price objective on shares of Verve Therapeutics from $56.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday, April 3rd. HC Wainwright initiated coverage on shares of Verve Therapeutics in a report on Monday, April 8th. They issued a “buy” rating and a $15.00 price objective for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price objective on shares of Verve Therapeutics in a report on Wednesday, February 28th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.